Drugs in MeSH Category Schistosomicides

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pfizer	VANSIL	oxamniquine	CAPSULE;ORAL	018069-001	Approved Prior to Jan 1, 1982		DISCN	No	No

Last updated: July 27, 2026

Schistosomicides (MeSH): Market Dynamics and Patent Landscape for Praziquantel, Oxamniquine, Artemisinin-Based Regimens, and Alternatives

Schistosomicides is a MeSH category that covers drug therapies used to treat schistosomiasis, including praziquantel-based standard of care and older agents (notably oxamniquine) in defined geographies. Patent and exclusivity risk is concentrated in (1) originator praziquantel IP around new formulations, pediatric dosing, and combination/regimen claims; (2) reformulation and manufacturing-process IP for tablets and fixed-dose combinations; and (3) method-of-use claims around artemisinin-based or combination regimens where new IP is being pursued. Across the category, the largest near-term generic threat is driven by praziquantel’s entrenched off-patent status in most markets, shifting the competitive battleground to formulation differentiation and regulatory strategy (e.g., pediatric labeling, bioequivalence, and line extensions).

Scope note: This analysis addresses schistosomicides at the class level (MeSH “Schistosomicides”), but the only way to map a credible, defensible patent landscape is to anchor it to specific active ingredients that are actually used in schistosomiasis programs and appear in patent filings and FDA/Orange Book-style regulatory tracking.

---

Which drugs fall under MeSH “Schistosomicides” and how do they drive market demand?

Core market-active agents in practice

• Praziquantel: the global backbone for schistosomiasis control programs and case management.
• Oxamniquine: largely regionally used historically; modern supply is more limited.
• Artemisinin derivatives (for schistosomiasis regimens, typically off-label or programmatic): artemether-artesunate or other artemisinin-based combination regimens used in certain strategies for S. mansoni and related species (policy-driven rather than single-ingredient “schistosomicide” exclusivity).
• Other schistosomiasis-active compounds: often sit in trial pipelines (not yet stable commercial revenue centers like praziquantel).

Demand drivers that shape patent strategy

• Program procurement: mass drug administration (MDA) and donated-supply models reduce sponsor willingness to build narrow IP around incremental changes unless they protect supply-chain value (formulation, heat stability, packaging, pediatric usability).
• Formulation and logistics: low-dose accuracy, palatability, heat stability in endemic regions, and acceptable administration devices matter as much as molecular novelty.
• Species and regimen differentiation: claims and investments target S. haematobium and S. mansoni treatment outcomes, plus reduced-dose pediatric programs.

Commercial reality

• Praziquantel dominates volume; branded pricing leverage is limited by long generics availability.
• IP value concentrates in line extensions: better formulation properties, fixed-dose combinations, or clear regimen claims that survive generic design-around.

---

What is the Orange Book status of praziquantel and what patents still matter?

Featured snippet answer

• Praziquantel is widely generic in the US, with most originator product patents long expired. Remaining patent value typically sits in formulation, method-of-use, pediatric dosing, or specific manufacturing-process claims, not the core drug substance.

How to interpret “still matters” in schistosomicides

• For schistosomicides, the Orange Book typically underrepresents value because many key patents are not tied to listed drug products or are filed in non-US jurisdictions.
• Where new patents exist, they often correspond to:
  • Improved immediate-release tablets or scored tablets for dose flexibility
  • Pediatric formulations (lower-strength tablets, dispersible formats, granulates)
  • Bioavailability-enhancing compositions for reduced dose schedules
  • Fixed-dose combinations (less common for praziquantel, but relevant as combination therapy trends grow)
  • Regimen claims with artemisinin-based partners

Patent estate structure for praziquantel

• Drug substance: largely expired.
• Drug product: replacement formulation IP is the main residual.
• Regulatory exclusivity: even when product exclusivity exists (e.g., new pediatric labeling), it does not block generic entry as strongly as composition-of-matter, and it is often time-limited to specific labeling and product codes.

---

How does patent expiration timing affect generic entry for praziquantel in schistosomiasis programs?

Featured snippet answer

• For praziquantel, generic entry risk is generally low for drug substance because most relevant patents have expired, so timing risk is mostly about product-specific patents expiring and the extent to which those patents are enforced for specific dosage forms.

Generic entry mechanics

• In practice, the market clears on:
  • Formulation/patent linkage: whether a generic can choose a non-infringing formulation design.
  • Regulatory strategy: bioequivalence and labeling pathways that avoid patent-protected claims.
  • Program adoption: MDA logistics can slow switching even when legal barriers are gone.

Key timing windows operators track

• Composition and formulation patent expirations (tablets vs dispersible forms).
• Method-of-use/regimen patent expirations tied to specific species-treatment claims or combination timing.
• Labeling changes that may trigger new exclusivity or force new Paragraph IV-style legal scrutiny.

---

What patents protect praziquantel formulations and dosing, and where are the likely weak points?

Patent categories that commonly appear in reformulation strategies

1. Pharmaceutical composition patents
   • Excipients optimized for dissolution and stability
   • Particle-size or polymorph claims (where applicable)
2. Dosage form patents
   • Tablets engineered for split dosing
   • Pediatric or taste-masked formulations
3. Manufacturing process patents
   • Granulation and tableting steps that change dissolution rate or stability
4. Method-of-use patents
   • Species-specific dosing schedules
   • Combination regimen timing and sequence (especially with artemisinin derivatives)

Where weak points appear

• Generics can often design around:
  • Excipients and process steps
  • Target product profiles by matching dissolution profiles through alternate excipient systems
• Method-of-use claims are harder to design around if enforcement ties directly to clinical labeling and prescriber instructions, but these claims often require strong evidence and are jurisdiction-dependent.

---

Which patent estates are most active around artemisinin-based schistosomiasis regimens?

Featured snippet answer

• Patent activity is concentrated in combination regimen claims and method-of-treatment frameworks rather than artemisinin “schistosomicide” single-agent composition claims.

What is protected

• Treatment regimens: timing and dosing sequence when combining artemisinin derivatives with praziquantel or when used as alternative strategies in S. mansoni treatment.
• Combination product formulations: fewer commercial fixed-dose combinations exist than co-administered regimens; where fixed-dose products exist, product-composition and manufacturing IP can carry longer tail value.
• Clinical protocol-like claims: dose per kilogram, number of days, and outcome endpoints (egg reduction, cure rates).

Why this matters commercially

• The procurement system often chooses based on:
  • Evidence strength for efficacy
  • Safety in children and pregnancy categories
  • Program fit and supply continuity
• IP that ties to dosing schedules can slow adoption of generics for regimen-specific products even when drug substance is generic.

---

How many patents cover oxamniquine and what is the market trajectory for schistosomiasis indications?

Featured snippet answer

• Oxamniquine is not a current global procurement anchor at the same scale as praziquantel. Patent value, where it exists, is typically limited to specific markets and product-form factor changes rather than broad global substance exclusivity.

Commercial and IP implications

• If oxamniquine supply is narrow, enforcement can be more about:
  • Maintaining supply chain reliability
  • Blocking generics in specific jurisdictions where originator-like formulations persist
• For most investors, oxamniquine is more of a historical comparator than a central revenue driver.

---

What patent litigation affects schistosomicides, and how does it shape supply outcomes?

Featured snippet answer

• Litigation risk in schistosomicides is generally less about large “Paragraph IV mass” campaigns and more about:
  • Targeted formulation/method-of-use disputes
  • Enforcement against specific dosing formats used by public health programs

How litigation changes the business

• Even when the scientific patent basis is narrow, litigation can:
  • Delay tender inclusion of certain SKUs
  • Reallocate procurement choices to products with fewer legal exposures
  • Push generic manufacturers into design-around formulations or alternate label pathways

---

Which companies are competing in schistosomicides and how do patent barriers shift market share?

Featured snippet answer

• The competitive field for praziquantel is dominated by generic supply. Patent barriers mostly affect which dosage forms get tender approval and which label claims remain tied to originator/regimen evidence.

Competition by “IP-relevant axis”

• Generic manufacturers win where they can:
  • Meet bioequivalence for specific strengths
  • Avoid formulation/method-of-use infringement
  • Offer stable supply with acceptable local packaging
• Originators win on:
  • Documented regimen evidence packaged with label-specific claims
  • Formulations tuned to program logistics (stability, administration, pediatric usability)
  • Any remaining defensible product patents in select jurisdictions

---

What generic entry risks exist for new praziquantel pediatric or fixed-dose formulations?

Featured snippet answer

• The generic entry risk is concentrated in product-specific patents for pediatric dosage forms and any fixed-dose combinations. Where these exist, generic manufacturers may face:
  • Paragraph IV-style challenges tied to formulation and use claims
  • Design-around requirements for excipients, dissolution profile, or dosing schedule

Risk vectors

• Bioequivalence not equal to non-infringement: a generic can pass BE and still infringe formulation or method-of-use claims.
• Label-driven enforcement: claims that map directly to indications or dosing instructions are harder for generics to avoid if the generic seeks similar labeling.

---

How does schistosomiasis exclusivity differ across geographies and regulatory systems?

Featured snippet answer

• Exclusivity in schistosomicides is jurisdiction-dependent and often driven by:
  • Local patent filing strategies
  • Product registration and pediatric labeling rules
  • Public health procurement rules that can decouple “legal expiry” from “market adoption”

Practical geographic patterns

• US/EU: strongest relevance of composition/formulation patents and Orange Book-style listings, plus FDA label-specific enforcement.
• Endemic region markets: patent enforcement can be weaker, but registration barriers, tender qualification, and supply continuity often determine entry speed.

---

What formulations are protected by current schistosomicides patents: tablets, dispersibles, and combinations?

Featured snippet answer

• Patent-protected space is dominated by oral solid formulations: immediate-release tablets, pediatric-strength tablets, and occasionally dispersible formats. Combination IP appears mainly in regimen claims and, where present, in co-formulation.

Formulation segments that attract patenting

• Low-dose pediatric tablets and scored tablets
• Stability-optimized excipient systems for endemic storage conditions
• Dissolution-profile modifications enabling dose schedules that differ from older generic references
• Taste-masking for pediatric acceptability (where dispersible or chewable forms exist)

---

Key takeaways on patent landscape for Schistosomicides

• Praziquantel anchors the category; most drug-substance exclusivity is long expired, shifting patent relevance to formulation, method-of-use/regimen, and manufacturing-process claims.
• Market dynamics favor procurement-ready products. IP that improves logistics and pediatric usability can extend commercial differentiation even when the active ingredient is generic.
• Patent and litigation risk is typically SKU-specific, not molecule-wide, so tender and product-line decisions should track claims by dosage form and label/regimen rather than assuming a full class exclusivity expiry.
• Artemisinin-based regimen IP, where it exists, tends to be method-of-treatment oriented. These claims can influence clinical adoption and label choices more than they block basic drug substance entry.

---

FAQs

1. Do formulation patents on praziquantel prevent generics even if drug substance is expired?
2. Are method-of-use schistosomiasis patents enforceable based on prescriber labeling in endemic countries?
3. How do pediatric dosing claims for praziquantel affect tender eligibility and generic substitution?
4. What is the patent strategy difference between co-administered regimen products and fixed-dose combinations?
5. When do regimen-protocol patents around artemisinin combinations become commercially irrelevant due to guideline updates?

---

References

No cited sources are available in the prompt to support an evidence-backed patent-by-patent landscape for specific schistosomicides (including exact patent numbers, assignees, expiration dates, Orange Book listings, and litigation dockets).